Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction To Survival Analysis01:18

Introduction To Survival Analysis

147
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
147
Actuarial Approach01:20

Actuarial Approach

50
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
50
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

71
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
71
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

110
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
110
Cancer Survival Analysis01:21

Cancer Survival Analysis

315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking success in modern urology.

BJU international·2026
Same author

Exploring the utility of artificial intelligence in identifying progression of prostate cancer during active surveillance: A systematic review.

Prostate cancer and prostatic diseases·2026
Same author

Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals.

medRxiv : the preprint server for health sciences·2026
Same author

Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy.

BJU international·2026
Same author

Use of MRI in the diagnosis of bladder cancer: a health economic analysis.

BJU international·2026
Same author

Leisure-Time Physical Activity and Cancer Mortality Among Cancer Survivors.

JAMA network open·2026
Same journal

Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer.

The Prostate·2026
Same journal

A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia.

The Prostate·2026
Same journal

Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United States.

The Prostate·2026
Same journal

Holmium Laser Enucleation of the Prostate (HoLEP) With Proactive Preservation of One Lateral Lobe: A Technique for Benign Prostatic Hyperplasia to Preserve Sexual Function.

The Prostate·2026
Same journal

Clinical Variable-Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation.

The Prostate·2026
Same journal

Association Between Intraoperative Prostate Bed Blood Flow and Postoperative Lower Urinary Tract Symptoms After Robot-Assisted Radical Prostatectomy.

The Prostate·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation.

Liang G Qu1,2, J Bailey Vaselkiv2, Marlon Perera3

  • 1Department of Urology, Monash Health, Berwick, Victoria, Australia.

The Prostate
|May 21, 2025
PubMed
Summary
This summary is machine-generated.

Patients with metastatic prostate cancer living in rural areas may experience slightly worse survival outcomes compared to those in urban settings. This finding highlights potential disparities in care for rural cancer patients.

Keywords:
SEER programprostatic neoplasmsrural healthsurvival analysis

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

  • Oncology
  • Epidemiology
  • Health Services Research

Background:

  • Urban-rural disparities in healthcare access and outcomes are a growing concern in oncology.
  • Prostate cancer survival may be influenced by geographic location, necessitating investigation into urban-rural differences.

Purpose of the Study:

  • To investigate the association between urban-rural status and survival in patients diagnosed with de novo metastatic prostate cancer.
  • To analyze potential differences in overall and cancer-specific survival based on residence.

Main Methods:

  • A cohort study using the Surveillance, Epidemiology, and End Results (SEER) database.
  • Inclusion of men aged ≤75 years diagnosed with metastatic prostate cancer (2009-2018).
  • Analysis of demographics, urban-rural status, and survival using Cox regression and restricted mean survival time (RMST) modeling.

Main Results:

  • 21,290 participants were analyzed, with differences noted in demographics between urban and rural cohorts.
  • Cox regression did not show a significant association between urban-rural status and overall or cancer-specific survival.
  • RMST modeling indicated urban patients lived 2.29 months longer than rural patients, a finding consistent across varying definitions of rurality.

Conclusions:

  • US individuals with de novo metastatic prostate cancer residing in rural areas may have slightly poorer survival compared to urban counterparts.
  • RMST analysis suggests a survival benefit for urban patients, even after accounting for histological subtypes and rurality definitions.